Company Spotlight: Alife Health Embryo Predict - AI Beats Unanimous Embryologist Consensus

This episode unpacks the FDA 510(k) clearance summary for Alife Health's Embryo Predict, an AI software tool designed to help embryologists select IVF embryos for transfer. Maya and Sam dive into the clinical trial numbers, including a retrospective study where the algorithm outperformed a unanimous consensus of five embryologists, while also examining the strict limitations and warnings the FDA placed on the final clearance.

Key points

• Embryo Predict is a software-only medical device that uses convolutional neural networks and patient metadata to generate a 0 to 1 score aiding in embryo selection.
• The FDA cleared it via the 510(k) pathway, determining it is substantially equivalent to a hardware-based predicate device, the Eeva System.
• In the LOTUS randomized controlled trial of 283 patients, the AI arm showed a 72.9% clinical pregnancy rate versus 68.0% for traditional morphology, proving non-inferiority.
• In the ROVER retrospective study, when all five evaluating embryologists agreed on the top embryo, the AI disagreed 31% of the time, and when it did, the AI achieved a higher clinical pregnancy rate.
• The FDA explicitly noted that the provided data does not support improved clinical pregnancy outcomes compared to the standard of care, and that performance may not reflect real-world community clinics.

Source: FDA 510(k) summary K250781: Embryo Predict (Alife Health) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Alife Health (alifehealth.com) · Product: Embryo Predict · FDA 510(k) K250781

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-alife-health-embryo-predict-ai-beats-unanimous-embry-a94eeb